(Q37626889)

English

ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

4 references

13 March 2019

17 June 2019

30 June 2019

14 November 2020

ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature (English)

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

rheumatoid arthritis

4 references

13 March 2019

17 June 2019

30 June 2019

14 November 2020

disease-modifying antirheumatic drug

1 reference

14 November 2020

systematic review

1 reference

based on heuristic

inferred from title

Stefano Alivernini

object named as

Stefano Alivernini

1

0 references

object named as

Elisa Gremese

3

0 references

Gianfranco Ferraccioli

object named as

Gianfranco Ferraccioli

5

0 references

4

object named as

Angelo Zoli

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

author name string

Antonella Laria

2

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

3 November 2009

5 references

Europe PubMed Central

PMC publication ID

21 August 2017

13 March 2019

17 June 2019

30 June 2019

14 November 2020

Arthritis Research and Therapy

5 references

Europe PubMed Central

PMC publication ID

21 August 2017

13 March 2019

17 June 2019

30 June 2019

14 November 2020

11

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

R163

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

4 references

Europe PubMed Central

13 March 2019

Europe PubMed Central

17 June 2019

Europe PubMed Central

30 June 2019

Europe PubMed Central

14 November 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

https://scigraph.springernature.com/pub.10.1186/ar2848

0 references

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003527

23 August 2017

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003527

23 August 2017

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003527

23 August 2017

Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003527

23 August 2017

Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003527

23 August 2017

Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003527

23 August 2017

Comparison of the efficacy of the tumour necrosis factor blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003527

23 August 2017

Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003527

1 September 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003527

1 September 2018

Switching between anti-TNFalpha agents: what is the evidence?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003527

1 September 2018

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3003527

3 December 2018

Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept

1 reference

https://pubmed.ncbi.nlm.nih.gov/19886983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/19886983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of efficacy of a third tumour necrosis factor α antagonist after failure of a soluble receptor and a monoclonal antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/19886983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept

1 reference

https://pubmed.ncbi.nlm.nih.gov/19886983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/19886983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/19886983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Residual minimal disease activity in rheumatoid arthritis: a simple definition through an in-depth statistical analysis of the major outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/19886983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37626889&oldid=1739281382"